Acetyl Octapeptide-3
Also known as: SNAP-8, Acetyl Glutamyl Octapeptide-3
Acetyl Octapeptide-3 (also called SNAP-8 or Acetyl Glutamyl Octapeptide-3) is a cosmetic SNARE-targeting peptide. Acetyl octapeptide-3, sold as SNAP-8, is an elongated analog of acetyl hexapeptide-8 carrying two additional residues, designed as a mimetic of the N-terminal region of SNAP-25.
For research use only.
Key Facts
- CAS
- 868844-74-0
- Molecular Weight (MW)
- ≈1075.2 g/mol
- Half-life
- Topical; systemic PK not established
- FDA status
- Not Approved
- Evidence level
- Limited Human Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- SNAP-25 / SNARE complex
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 26
- Listed offers
- 38
- Median price per mg (peptide vials)
- $3.45/mg
- Typical $3.00–$4.17/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials25 vendors · median $3.45/mg
- Bulk powders2 vendors · $0.200/mg
Research summary
Elongated Argireline analog (SNAP-8) used in topical cosmetics. Not an FDA-approved drug; not WADA-prohibited as a cosmetic peptide.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials1 reviewed source
- Early or uncontrolled human studies1 reviewed source
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Acetyl Octapeptide-3 profile summarises 2 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Acetyl Octapeptide-3 dosage: no established human dose
Acetyl octapeptide-3 (SNAP-8) has no established human dosage. It is a cosmetic ingredient, and its human studies test skin products that also contain other actives. In a placebo-controlled study, 24 adults wore a dissolving microneedle patch containing it under one eye overnight, with assessments over 28 days. No study has injected it.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Acetyl octapeptide-3 is an eight-amino-acid peptide related to acetyl hexapeptide-8 and used in anti-wrinkle cosmetics. The human studies found test multi-ingredient patches, so they cannot isolate its effect or define a strength. No study has given it to people by injection, so no injectable amount, route or interval is established.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Topical (cosmetic products and dissolving microneedle patches); not established for injection |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-11-07 |
Human research reported
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Placebo-controlled split-eye study — dissolving microneedle patch (Shin et al., 2024)Clinical trial · Placebo-controlled study of a multi-ingredient product | 24 healthy adults | Patch content not stated in the indexed abstract; the patch combined acetyl octapeptide-3 with ascorbyl glucoside and sodium cyclic lysophosphatidic acid on a hyaluronic acid base, vs a hyaluronic acid-only patch | Topical (dissolving microneedle patch under the eye) | Applied overnight | Assessments over 28 days | Better eye-wrinkle improvement, lower water loss and better elasticity and lifting than the placebo patch; no adverse effects | Shin JY et al. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol. 2024. |
| Open clinical study — hyaluronic acid microneedle patch (Avcil et al., 2020)Clinical trial · Single-centre study without a stated control group | Healthy adults with aged skin (number not stated in the indexed abstract) | Not stated in the indexed abstract; the patch combined arginine/lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts | Topical (microneedle patch at the outer eye corners and the forearm) | — | 12 weeks | Fine lines and wrinkles 25.8% lower, hydration 15.4% higher, dermal density and thickness 14.2% and 12.9% higher; no skin reactions | Avcil M et al. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol. 2020. |
Where sources disagree
- SNAP-8 is widely sold as lyophilised powder vials (most often 10 mg or 20 mg). No human study has injected it at any amount, so injection protocols have no primary source; its studied use is on the skin.
- A percentage or ppm in a cream is a formulation strength, not a dose, and cannot be converted into an amount for injection.
- Evidence for acetyl hexapeptide-8 (Argireline) is not evidence for acetyl octapeptide-3; they are different peptides.
Reconstitution
Common research vial sizes: 10 mg, 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL | 50 mcg per 0.01 mL |
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Sequence & molecular data
| Molecular formula | C41H70N16O16S |
|---|---|
| Molecular weight | ≈1075.2 g/mol |
| CAS number | 868844-74-0 |
| Half-life | Topical; systemic PK not established |
| Appearance | White powder |
| Formulation | Topical Cream |
| PubChem CID | 76283482 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Acetyl octapeptide-3, sold as SNAP-8, is an elongated analog of acetyl hexapeptide-8 carrying two additional residues, designed as a mimetic of the N-terminal region of SNAP-25. Like its shorter relative it is proposed to compete for a position in the SNARE complex that mediates neurotransmitter vesicle fusion, destabilising assembly and reducing calcium-dependent transmitter release in model systems, with the cosmetic aim of softening lines produced by repeated muscle contraction. The extension is claimed by suppliers to improve activity relative to the hexapeptide. Independent comparative data is scarce, and as with all peptides of this size penetration through intact stratum corneum is the limiting factor.
Origin
Synthetic acetylated octapeptide.
Targets
Studies
Research statistics
2 PubMed publications · 100.0% human clinical research · 0 registered trials
Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Acetyl Octapeptide-3 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | OTC / Supplement |
| WADA (sport) | Permitted |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Acetyl Octapeptide-3 side effects
Acetyl Octapeptide-3 has only limited human data, so the list below is incomplete and its side-effect profile is not well established.
Side Effects
- Mild irritation
- Redness
Stacking
Common stacking partners
Combinations that include Acetyl Octapeptide-3, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Cosmetic peptides in this library are formulated into topical products; follow the product label rather than the reconstitution guidance above.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Acetyl Octapeptide-3: frequently asked questions
What is Acetyl Octapeptide-3?
Elongated Argireline analog (SNAP-8) used in topical cosmetics. Not an FDA-approved drug; not WADA-prohibited as a cosmetic peptide.
How does Acetyl Octapeptide-3 work?
Acetyl octapeptide-3, sold as SNAP-8, is an elongated analog of acetyl hexapeptide-8 carrying two additional residues, designed as a mimetic of the N-terminal region of SNAP-25. Like its shorter relative it is proposed to compete for a position in the SNARE complex that mediates neurotransmitter vesicle fusion, destabilising assembly and reducing calcium-dependent transmitter release in model systems, with the cosmetic aim of softening lines produced by repeated muscle contraction.
Is Acetyl Octapeptide-3 FDA approved?
No. Acetyl Octapeptide-3 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Acetyl Octapeptide-3?
Reported half-life for Acetyl Octapeptide-3 is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Acetyl Octapeptide-3 banned in sport?
Acetyl Octapeptide-3 is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Acetyl Octapeptide-3?
Compounds most often compared with Acetyl Octapeptide-3 include Acetyl Hexapeptide-8, Acetyl Tetrapeptide-3, AHK-Cu and Biotinoyl Tripeptide-1. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- INCI / PubChem SNAP-8External reference
- Class-level evidence — D-tyrosine adds an anti-melanogenic effect to cosmetic peptides — Sci Rep, 2020External reference
- Class-level evidence — In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation — Cutan Ocul Toxicol, 2015External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Acetyl Octapeptide-3 profile is compiled from published literature (2 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Acetyl Octapeptide-3 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →